TG
DNLI icon

TCW Group’s Denali Therapeutics DNLI Stock Holding History

TCW Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-141,924
Closed -$2.93M – 373
2023
Q3 		$2.93M Buy
141,924
+51,953
+58% +$1.32M 0.04% 199
2023
Q2 		$2.66M Buy
89,971
+1,660
+2% +$46.7K 0.03% 218
2023
Q1 		$2.03M Buy
88,311
+49,280
+126% +$1.36M 0.03% 214
2022
Q4 		$1.09M Buy
+39,031
New +$1.16M 0.02% 246

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCW Group's DNLI Position: Q4 2023 in Review

TCW Group sold out of Denali Therapeutics (DNLI) in Q4 2023, closing a stake of 141,924 shares — an estimated $2.93M sold.

TCW Group first reported a position in DNLI in Q4 2022 and held it in 4 quarters. The position peaked at $2.93M in Q3 2023. 209 funds tracked by Wall St. Rank hold DNLI as of Q4 2023.

  • TCW Group reported no remaining Denali Therapeutics position as of Q4 2023 after selling out during the quarter.
  • TCW Group sold 141,924 Denali Therapeutics shares in Q4 2023, an estimated $2.93M.
  • TCW Group first reported a position in Denali Therapeutics in Q4 2022 and held it in 4 quarters.
  • TCW Group's Denali Therapeutics position peaked at $2.93M in Q3 2023.
  • 209 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2023.

Based on TCW Group's 13F filing for Q4 2023, filed 9 Feb 2024.